


Amendments to the Claims:

The following listing of claims replaces all prior versions and listings of the claims in this application.

Listing of the Claims:


1. (Currently Amended) A compound of general formula II



II

wherein R_1 , R_2 , R_3 and R_4 are independently hydrogen or a group that liberates the free amine *in vivo*, for example -CO-alkyl, preferably -CO- C_1 - C_3 alkyl or pivalate; or -CO-haloalkyl, preferably -CO- C_1 - C_3 haloalkyl, most preferably -CO- C_1 - C_3 chloroalkyl ;

wherein W is;



and @ denotes the points of attachment and wherein the ester can be located in either direction;

wherein n and m are independently 0-5 ;





wherein one but not both of X and Y can be nitrogen, or X is C-A and/or Y is C-B;




wherein A and B are independently selected from hydrogen, alkyl optionally substituted with a halogen, amino, alkylamino, dialkylamino, hydroxy, nitro, cyano, trihaloalkyl, amido, alkoxy or halogen; and pharmacologically acceptable salts thereof;

~~Provided~~ provided that when R₁ to R₄ are hydrogen, both X and Y are C-H, n is 1 and - (CH₂)_n- is attached to the bridging oxygen of the ester group W, then m cannot be 0 or 1.

2. (Original) A compound as claimed in claim 1 wherein X is C-A and Y is C-B.

3. (Currently Amended) A compound having one of the following formulae:

1:1		2-[4-(2,4-Diamino-quinazolin-6-yl)oxycarbonylmethyl]-benzoylamino]-pentanedioic acid
1:2		2-[4-(2,4-Diamino-quinazolin-6-yl)oxycarbonyl]-benzoylamino]-pentanedioic acid
1:3		2-{4-[2-(2,4-Diamino-quinazolin-6-yl)methoxycarbonyl]-ethyl}-benzoylamino]-pentanedioic acid
1:4		2-{4-[2-(2,4-Diamino-quinazolin-6-yl)-ethoxycarbonylmethyl]-benzoylamino]-pentanedioic acid

2:1		2-{4-[2-(2,4-Diamino-quinazolin-6-yl)-acetoxy]-benzoylamino}-pentanedioic acid
2:2		2-[4-(2,4-Diamino-quinazoline-6-carbonyloxy)-benzoylamino]-pentanedioic acid
2:3		2-{4-[3-(2,4-Diamino-quinazolin-6-yl)-propionyloxymethyl]-benzoylamino}-pentanedioic acid

4. (Currently Amended) A compound as claimed in claim 1 ~~any of the previous claims~~, which additionally comprises ~~comprise~~ a label, preferably a radioactive label, or a toxic agent.


5. (Currently Amended) A pro-drug from which a compound as claimed in claim 1 ~~any one of the claims 1 to 3~~ can be formed in vivo.

6. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim 1 ~~any one of the claims 1 to 4 or a pro-drug as claimed in claim 5~~, together with one or more carriers, adjuvants or excipients.


7. (Cancelled).

8. (Currently Amended) A process for the production of a compound as claimed in claim 1, which comprises a reaction as given in scheme 1 or 2.

Scheme 1



Scheme 2



9-11. (Cancelled).

12. (Currently Amended) Method for treating a disease diseases which can be therapeutically treated by immuno-modulating or cytostatic compounds, in particular dihydrofolate reductase inhibitors, either applied topically, orally or parenterally, or cancer forms being sensitive to methotrexate, IBD, i. e. ulcerative colitis and Crohn's disease, colorectal cancer, asthma, or other serious pulmonary diseases, PCP, psoriasis, inflammations caused by bacteria, fungi, protozoa, ~~rheumatoid arthritis as well as other inflammatory conditions~~, rheumatoid arthritis as well as other inflammatory conditions, cancer of the urinary bladder, the skin, the lung and other cancer types that are reachable by topical

application, non-surgical abortions (intrauterin administration), liver and intestine transplantations by preventing immunogenic rejection reactions, whereby a therapeutically effective amount of at least one compound defined in claim 1 ~~claims 1-4~~ is administered for a time sufficient to substantially eliminate the signs and symptoms of such a disease

13. (Currently Amended) A method for the treatment of a disease, which is sensitive to an inhibition of dihydrofolate reductase comprising the administration of a therapeutically active amount of at least one compound as; defined in claim 1 ~~any of claims 1-4~~.

14. (Currently Amended) A method according to claim 12 for the treatment of cancer forms being sensitive to methotrexate, ~~comprising the administration of a therapeutically active amount of at least one compound as defined in any of claims 1-4.~~

15. (Currently Amended) A method according to claim 12 for the treatment of IBD, ~~comprising the administration of a therapeutically active amount of at least one compound as defined in any of claims 1-4.~~

16. (Currently Amended) A method according to claim 12 for the treatment of PCP, ~~comprising the administration of a therapeutically active amount of at least one compound as defined in any of claims 1-4.~~

17. (Currently Amended) A method according to claim 12 for the treatment of psoriasis, ~~comprising the administration of a therapeutically active amount of at least one compound as defined in any of claims 1-4.~~

18. (Currently Amended) A method according to claim 12 for the treatment of rheumatoid arthritis, ~~comprising the administration of a therapeutically active amount of at least one compound as defined in any of claims 1-4.~~
19. (Currently Amended) A method according to claim 12 for the treatment of inflammation ~~inflammations~~ caused by fungal, protozoal and/or bacterial infections, ~~comprising the administration of a therapeutically active amount of at least one compound as defined in any of claims 1-4.~~
20. (Currently Amended) A method according to claim 12 for the treatment of asthma or ~~and~~ pulmonary disease ~~diseases~~ ~~comprising the administration of a therapeutically active amount of at least one compound as defined in any of claims 1-4.~~
21. (Currently Amended) A method according to claim 12 for the treatment of liver or ~~and~~ intestine transplantation ~~transplantations~~ by preventing immunogenic rejection reactions, ~~comprising the administration of a therapeutically active amount of at least one compound as defined in any of claims 1-4.~~
22. (Currently Amended) A method for the treatment of disease ~~diseases~~ or condition ~~conditions~~ related to the melanocortin system comprising the administration of a therapeutically active amount of at least one compound as defined in claim 1 ~~in any of claims 1-4.~~

23. (New) A pharmaceutical composition comprising a pro-drug as claimed in claim 5, together with one or more carriers, adjuvants or excipients.

24. (New) A method for the treatment of inflammation, comprising administering a compound as defined in claim 1.

25. (New) A method for the treatment of inflammation, comprising administering a pro-drug as defined in claim 5.